

RECEIVED
CENTRAL FAX CENTER

JUN 23 2004



901 California Avenue

Palo Alto, CA 94304-1104

Main: 650 • 496-6400

FAX: 650 • 496-1200

FAX TRANSMITTAL SHEET

OFFICIAL

NO. OF PAGES (including this page): 9**TO:** Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**Attn:** Examiner
Art Unit: 1646
FAX: (703) 872-9306**FROM:** Sheela Mohan-Peterson
DATE: June 23, 2004**RE:** Docket No.: DX0763XB1
USSN: 10/775,640
Filed: February 10, 2004
Title: Mammalian Cell Membrane Proteins; Related Reagents**Any difficulty with this facsimile, please call: Melanie Lyons at (650) 496-1183****Documents attached:**

- Transmittal (1 page)
- IDS and Form PTO/SB/08 (7 pages)

I hereby certify that this correspondence is being facsimile transmitted to the USPTO to:
Commissioner for Patents, Washington, DC 20231, on the date indicated below:

June 23, 2004
Melanie Lyons

CONFIDENTIALITY NOTE: This sheet and/or the document(s) accompanying it contain information belonging to DNAX which is confidential and/or legally privileged. The information is intended only for the use of the person or entity named above. If you have received this fax in error, please immediately notify us by telephone or return Fax.

PTO/SB/21 (03-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

TRANSMITTAL FORM (to be used for all correspondence after Initial filing)	Application Number	10/775,640	
	Filing Date	02/10/2004	
	First Named Inventor	Alexander B.H. BAKKER	
	Art Unit	1646	
	Examiner Name		
Total Number of Pages in This Submission	9	Attorney Docket Number	DX0763XB1


ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (2 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Other Enclosures/Remarks: • Form PTO/SB/08 (5 pages) • Fax Transmittal Sheet (1 page)
--	---	--

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual	Sheela Mohan-Peterson, Reg. No. 41,201 DNAX Research, Inc. 901 California Ave. Palo Alto, CA 94304-1104
Signature	
Date	23-June-2004

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this date indicated below:			
Typed or printed	MELANIE LYONS		
Signature		Date	6-23-04

This collection of information is required by 37 CFR 1.52. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Attorney Docket: DX0763XB1

RECEIVED
CENTRAL FAX CENTER

JUN 23 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re application of:
Alexander B. H. BAKKER, et al.

Examiner: Not yet assigned

Art Unit: 1646

Application No.: 10/775,640

Conf. No.: 1877

Filed: February 10, 2004

For: MAMMALIAN CELL MEMBRANE
PROTEINS; RELATED REAGENTSI hereby certify that this correspondence is being facsimile
transmitted to the USPTO, addressed to: Commissioner for
Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on
June 23, 2004Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

by:


MELANIE LYONSINFORMATION DISCLOSURE STATEMENT

Sir:

The materials as listed in the attached form PTO/SB/08 are brought to the Examiner's attention pursuant to the duty of disclosure under 37 C.F.R. § 1.56, § 1.97, and § 1.98. Attached please find Form PTO/SB08 listing references AA-CE.

All references listed on the attached form PTO/SB/08 have been previously cited either by Applicants or the Examiner in the parent applications, U.S. Patent Application No. 09/127,946, filing date July 31, 1998 (now US Patent No. 6,416,973), and 10/191,732, filing date July 8, 2002, and copies should be available there. As such, these references will not be provided absent a specific request.

Citation of these documents should not be construed as a representation that the documents are in fact material or are in fact prior art with respect to the instant invention. The Examiner should not make any inference relating to the relative pertinence of cited references based upon the order in which the art is presented. Citation of these documents should not be construed as a representation that a search has been made or that more pertinent art may not be in existence.

Applicants request that the Examiner fully consider the art cited in the attached PTO/SB/08 form. Applicants further request that the Patent and Trademark Office list all such art on the front of any patent issuing from this application.

Applicants believe no fee is required for filing this document; however, if such a fee is required the Commissioner is hereby authorized to charge DNAX Research Institute Deposit account no. 04-1239.

Respectfully submitted,

Date: 23-June-2004

By: Sheela Mohan-Peterson
Sheela Mohan-Peterson, Reg. No. 41,201
Attorney for Applicants

Customer No. 28008
DNAX Research, Inc.
901 California Avenue
Palo Alto, CA 94304-1104
Telephone (Switchboard): (650) 496-6400
Telephone No. (Direct): (650) 496-1244
Facsimile No.: (650) 496-1200

PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/775,640
				Filing Date	02/10/2004
				First Named Inventor	Alexander B.H. BAKKER
				Art Unit	1646
				Examiner Name	
Sheet	1	of	5	Attorney Docket Number	DX0763XB1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	DOCUMENT NUMBER Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear
	AA	US 2003/0022279 A1	1/30/03	Fraser et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code* Number* Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear	T ³
	AB	WO 94/01548	1/20/94	Medical Research Council		
	AC	WO 96/26961	9/6/98	Nat. Jewish Center for Immunolo., et al.		
	AD	WO 97/20046	6/5/97	Schering Corporation		
	AE	WO 98/39446	9/11/98	Human Genome Sciences		
	AF	WO 98/49292	11/5/98	Inst. Nat. Sante. Rech. Med., et al.		
	AG	WO 99/06548	2/11/99	Genset		
	AH	WO 99/06554	2/11/99	Genset		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/775,840
				Filing Date	02/10/2004
				First Named Inventor	Alexander B.H. BAKKER
				Art Unit	1646
				Examiner Name	
Sheet	2	of	5	Attorney Docket Number	DX0763XB1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AJ	José Aramburu, et al., <u>The Journal of Immunology</u> , 144(8):3238-3247, April 15, 1990 "A novel functional cell surface dimer (Kp43) expressed by natural killer cells and T cell receptor-γ/δ TCR ⁺ T lymphocytes I. Inhibition of the IL-2-Dependent Proliferation by Anti-Kp43 Monoclonal Antibody"	
	AJ	José Aramburu, et al., <u>The Journal of Immunology</u> , 147(2):714-721, July 15, 1991 "A novel functional cell surface dimer (Kp43) expressed by natural killer cells and T cell receptor-γ/δ TCR ⁺ T lymphocytes II. Modulation of Natural Killer Cytotoxicity by Anti-Kp43 Monoclonal Antibody"	
	AK	A. Bernot, et al., <u>GenBank</u> , Accession No. M88072, June 24, 1994. Definition: "Gallus gallus (17.5) mRNA, complete cds."	
	AL	Mathieu Bléry, et al., <u>J. Biol. Chem.</u> , 272(14):8989-8996, April 4, 1997. "Reconstituted Killer Cell Inhibitory Receptors for Major Histocompatibility Complex Class I Molecules Control Mast Cell Activation Induced via Immunoreceptor Tyrosine-based Activation Motifs"	
	AM	John C. Cambier, <u>Immunology Today</u> , 16(2):110, 1995. "New nomenclature for the Reth motif (or ARH1/TAM/ARAM/YXXL)"	
	AN	John C. Cambier, et al., <u>Proc. Natl. Acad. Sci. USA</u> , 94:5993-5995, June 1997. "Inhibitory receptors abound?"	
	AO	Marco Colonna, <u>NATURE</u> , 391:642-643, February 12, 1998. "Unmasking the killer's accomplice"	
	AP	Marco Colonna and Jacqueline Samaridis, <u>SCIENCE</u> , 268:405-408, April 21, 1995. "Cloning of Immunoglobulin-Superfamily Members Associated with HLA-C and HLA-B Recognition by Human Natural Killer Cells"	
	AQ	Marc Daëron, et al., <u>Immunity</u> , 3:635-646, November 1995. "The Same Tyrosine-Based Inhibition Motif, in the Intracytoplasmic Domain of FCγRIIB, Regulates Negatively BCR-, TCR-, and FcR-Dependent Cell Activation"	
	AR	A. D'Andrea, et al., <u>The Journal of Immunology</u> , 155:2306-2310, 1995. "Molecular Cloning of NKB1, A Natural Killer Cell Receptor for HLA-B Allotypes"	
	AS	R. Giorda, et al., <u>GenBank</u> , Accession No. M62891, September 14, 1992. Definition: "R.norvegicus 3.2.3 antigen protein mRNA, complete cds."	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/775,640
				Filing Date	02/10/2004
				First Named Inventor	Alexander B.H. BAKKER
				Art Unit	1646
				Examiner Name	
Sheet	3	of	5	Attorney Docket Number	DX0763XB1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AT	J. Hamann, et al., <u>GenBank</u> , Accession No. L07555, April 21, 1997. Definition: "Homo sapiens early activation antigen CD69 mRNA, complete cds."	
	AU	L. Hillier, et al., <u>GenBank</u> , Accession No. AA412675, May 2, 1997. Definition: "zu12c03.s1 Soares testis_NHT Homo sapiens cDNA clone IMAGE:731620 3', MRNA sequence"	
	AV	L. Hillier, et al., <u>GenBank</u> , Accession No. AA480109, August 8, 1997. Definition: "zv41f05.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone 756225 3' similar to TR:G498729 G498729 ZINC FINGER PROTEIN"	
	AW	L. Hillier, et al., <u>GenBank</u> , Accession No. AA481924, August 8, 1997. Definition: "zv41f05.r1 Soares ovary tumor NbHOT Homo sapiens cDNA clone 756225 5' similar to TR:G498729 G498729 ZINC FINGER PROTEIN"	
	AX	L. Hillier, et al., <u>GenBank</u> , Accession No. H12338, June 27, 1995. Definition: "yj11h03.s1 Homo sapiens cDNA clone 148469 3'."	
	AY	L. Hillier, et al., <u>GenBank</u> , Accession No. H12392, June 27, 1995. Definition: "yj11h03.r1 Homo sapiens cDNA clone 148469 5'."	
	AZ	L. Hillier, et al., <u>GenBank</u> , Accession No. H39980, August 16, 1995. Definition: "yjo55g07.r1 Homo sapiens cDNA clone 181884 5'."	
	BA	L. Hillier, et al., <u>GenBank</u> , Accession No. N41026, January 22, 1996. Definition: "yy53c02.s1 Homo sapiens cDNA clone 277250 3' similar to PIR:S47066 S47066 zinc finger protein - human."	
	BB	L. Hillier, et al., <u>GenBank</u> , Accession No. R49793, May 18, 1995. Definition: "yj55f08.r1 Homo sapiens cDNA clone 152679 5'."	
	BC	L. Hillier, et al., <u>GenBank</u> , Accession No. T52100, February 8, 1995. Definition: "yb10h09.r1 Homo sapiens cDNA clone 70817 5'."	
	BD	L. Hillier, et al., <u>GenBank</u> , Accession No. T55959, February 8, 1995. Definition: "yb35f06.r1 Homo sapiens cDNA clone 73187 5'."	
	BE	L. Hillier, et al., <u>GenBank</u> , Accession No. W60864, October 15, 1996. Definition: "zd27g05.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 341912 3' similar to PIR:S47068 S47066 zinc finger protein - human"	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
 If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/775,640	
			Filing Date	02/10/2004	
			First Named Inventor	Alexander B.H. BAKKER	
			Art Unit	1646	
Examiner Name					
Sheet	4	of	5	Attorney Docket Number	DX0763XB1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BF	L. Hillier, et al., <u>GenBank</u> , Accession No. W60940, October 15, 1996. Definition: "zd27g05.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 341912 5'."	
	BG	L. Hillier, et al., <u>GenBank</u> , Accession No. W74783, October 16, 1996. Definition: "zd57c01.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 344738 5'."	
	BH	L. Hillier, et al., <u>GenBank</u> , Accession No. W92376, July 16, 1996. Definition: "zd99g11.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 357668 3' similar to PIR:S47066 S47066 zinc finger protein - human"	
	BI	Lewis L. Lanier, et al., <u>Immunity</u> , 8:693-701, June 1998. "Association of DAP12 with Activating CD94/NKG2C NK Cell Receptors"	
	BJ	Lewis L. Lanier, et al., <u>Nature</u> , 391:703-707, February 12, 1998. "Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells"	
	BK	Lewis L. Lanier, <u>Immunity</u> , 6:371-378, April 1997. "Natural Killer Cells: From No Receptors to Too Many"	
	BL	Paul J. Leibson, <u>Immunity</u> , 3:5-8, July 1995. "MHC-Recognizing Receptors: They're Not Just for T Cells Anymore"	
	BM	Bernard Malissen, <u>NATURE</u> , 384:518-519, December 12, 1996. "Two faces are better than one"	
	BN	M. Marra, et al., <u>GenBank</u> , Accession No. AA098506, October 25, 1996. Definition: "mo08f09.r1 Life Tech mouse embryo 10 5dpc 10665016 Mus musculus cDNA clone 553001 5'."	
	BO	M. Marra, et al., <u>GenBank</u> , Accession Number AA186015, February 17, 1997. Definition: "mt35c02.r1 Soares mouse 3NbMS Mus musculus cDNA clone IMAGE:623042 5' similar to SW:NK13_RAT P27471 NATURAL KILLER CELL SURFACE PROTEIN P1-3.2.3 ;, mRNA sequence.	
	BP	M. Marra, et al., <u>GenBank</u> , Accession No. AA242315, March 7, 1997. Definition: "mw26h05.r1 Soares mouse 3NMW12 5 Mus musculus cDNA clone 671865 5'."	
	BQ	M. Marra, et al., <u>GenBank</u> , Accession No. AA138406, February 16, 1997. Definition: "mr12f09.r1 Soares mouse 3NbMS Mus musculus cDNA clone 597257 5'."	
	BR	M. Marra, et al., <u>GenBank</u> , Accession No. W41142, September 11, 1996. Definition: "mc38h03.r1 Soares mouse p3NMF19.5 Mus musculus cDNA clone 350837 5'."	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 808. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-6199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete If Known

Application Number	10/775,640
Filing Date	02/10/2004
First Named Inventor	Alexander B.H. BAKKER
Art Unit	1646
Examiner Name	
Attorney Docket Number	DX0763XB1

Sheet 5 of 5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BS	M. Marra, <i>et al.</i> , <u>GenBank</u> , Accession No. W88159, September 12, 1996. Definition: "mf69f10.r1 Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone 419563 5'."	
	BT	M. Marra, <i>et al.</i> , <u>GenBank</u> , Accession No. W91184, September 12, 1996. Definition: "mf72b05.r1 Soares mouse embryo 3NbME13.5 14.5 Mus musculus cDNA clone 419793 5'."	
	BU	M. Marra, <i>et al.</i> , <u>GenBank</u> , Accession Number W13188, October 2, 1997. Definition: mb31f12.r1 Soares mouse p3NMF19.5 Mus musculus cDNA clone IMAGE:331055 5', mRNA sequence.	
	BV	Alessandro Moretta, <i>et al.</i> , <u>Annual Review of Immunology</u> , 14:619-648, 1996. "RECEPTORS FOR HLA CLASS-I MOLECULES IN HUMAN NATURAL KILLER CELLS"	
	BW	NCI-CGAP (Robert Strausberg), <u>GenBank</u> , Accession Number AA518481, January 5, 1996. Definition: nh52a05.r1 NCI_CGAP_Pr5 Homo sapiens cDNA clone IMAGE:955952, mRNA sequence.	
	BX	Lucia Olcese, <i>et al.</i> , <u>The Journal of Immunology</u> , 158:5083-5086, 1997. "Human Killer Cell Activatory Receptors for MHC Class I Molecules Are Included In a Multimeric Complex Expressed by Natural Killer Cells"	
	BY	Gonzalo Rubio, <i>et al.</i> , <u>The Journal of Immunology</u> , 151(3):1312-1321, August 1, 1993. "A Novel Functional Cell Surface Dimer (kp43) Serves as Accessory Molecule for the Activation of a Subset of Human $\gamma\delta$ T Cells"	
	BZ	Jacqueline Samardis and Marco Colonna, <u>Eur. J. Immunology</u> , 27:660-665, 1997. "Cloning of novel immunoglobulin superfamily receptors expressed on human myeloid and lymphoid cells: structural evidence for new stimulatory and inhibitory pathways"	
	CA	Andrew M. Scharenberg and Jean-Pierre Kinet, <u>Cell</u> , 87:981-984, December 13, 1996. "The Emerging Field of Receptor-Mediated inhibitory Signaling: SHP or SHIP?"	
	CB	Kathleen M. Smith, <i>et al.</i> , <u>The Journal of Immunology</u> , 161(1):7-10, July 1, 1998. "Cutting Edge: Ly-49D and Ly-49H Associate with Mouse DAP12 and Form Activating Receptors"	
	CC	Kan Takase, <i>et al.</i> , <u>The Journal of Immunology</u> , 159:741-747, 1997. "A New 12-Kilodalton Dimer Associated with Pre-TCR Complex and Clonotype-Independent CD3 Complex on Immature Thymocytes"	
	CD	Matthew L. Thomas, <u>Journal of Experimental Medicine</u> , 181:1953-1956, June 1995. "Of ITAMs and ITIMs: Turning On and Off the B Cell Antigen Receptor"	
	CE	Nicolai Wagtmann, <i>et al.</i> , <u>Immunity</u> , 2:439-449, 1995. "Molecular Clones of the p58 NK Cell Receptor Reveal Immunoglobulin-Related Molecules with Diversity in Both the Extra- and Intracellular Domains"	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.